The Global Alzheimer’s Disease Treatment Market Size accounted for USD 2,916 Million in 2021 and is anticipated to reach USD 8,411 Million by 2030 with a CAGR of 12.8% from 2022 to 2030.

Alzheimer's disease is a form of dementia that impairs thinking, behavior, and memory. Eventually, symptoms become severe enough to obstruct daily activities. The Alzheimer's Association estimates that 60 to 80 percent of dementia cases are caused by Alzheimer's disease. The disease is typically diagnosed in patients over the age of 65. Alzheimer's disease is typically described as having an "early onset" or "younger onset" if it is discovered earlier. Typically, the learning-related area of the brain is where Alzheimer's changes first manifest. Insidious confusion about events, time, and place; unfounded suspicions about friends, family, and professional caretakers; more severe memory loss and behavioral changes; and difficulty swallowing, speaking, and walking are just a few of the symptoms that become more severe as Alzheimer's spreads through the brain.

Market Dynamics

Up to 5.8 million Americans were expected to have Alzheimer's disease in 2020. 80 percent of them are 75 years of age or older. Between 60 and 70 percent of the 50 million or so dementia sufferers worldwide are thought to have Alzheimer's disease. Alzheimer's disease can affect younger people, but it is less common in them. Beyond the age of 65, the disease's prevalence doubles every five years. By 2060, this number is expected to nearly triple to 14 million. The disease can start to show symptoms after the age of 60, and the risk rises with age.

Alzheimer's disease is not a typical aspect of ageing. Ageing is the biggest risk factor currently understood, and people 65 and older make up the majority of Alzheimer's patients. If Alzheimer's disease develops in a person younger than 65, it is referred to as younger-onset Alzheimer's. Early-onset Alzheimer's disease is another name for younger-onset dementia.

One of the top 10 leading causes of death in the US is Alzheimer's disease. the sixth leading cause of death for adults in the US. the fifth most common cause of death for adults 65 and older. The estimated cost of treating Alzheimer's disease in 2010 ranged from USD 159 billion to USD 215 billion. These expenses are anticipated to increase to between USD 379 billion and more than USD 500 billion annually by 2040. Unlike heart disease and cancer, where death rates are declining, Alzheimer's disease death rates are rising. According to research, dementia, including Alzheimer's disease, is underreported on death certificates; as a result, the percentage of elderly people who pass away from Alzheimer's may be much higher.

Market Insights

The three categories of the global alzheimer’s disease treatment market are drug class, distribution channel, and region. The segmentation based on the drug class includes cell AChE inhibitors, cholinergic, combined drug, immunoglobulins, and memantine. Among them, cholinergic drug class is expected to lead the market with majority of the share. Cholinesterase inhibitors are one of the few drug therapies that have been clinically effective in the treatment of Alzheimer's disease dementia, validating the cholinergic system as a key therapeutic target in the disease. They improve the availability of acetylcholine at synapses in the brain.

Retail pharmacy, hospital pharmacy, and online sales are among the distribution channel segments included in the segmentation. Hospital pharmacy will record a significant market share in 2021 and is likely to continue its dominance throughout the forecast timeframe from 2022 to 2030. However, online sales is anticipated to witness a noteworthy growth rate in the coming years.

Global Alzheimer’s Disease Treatment Market Geographical Competition

The North American, European, Latin American, Asian-Pacific, Middle Eastern, and African regions make up the five geographical segments of the global Alzheimer’s Disease Treatment market. Due to its early adoption of cutting-edge technologies, expanding research and development capabilities, growing awareness of the treatment and control of chronic diseases, and well-organized regulatory framework, North America dominates the market for Alzheimer's disease treatments. During the forecast period, Asia-Pacific is expected to experience significant growth and achieve the highest CAGR. This is a result of rising healthcare infrastructure development costs, an increasing geriatric population, increased public awareness of Alzheimer's disease, and an increase in research and development activities.

Global Alzheimer’s Disease Treatment Industry Segment Analysis

Market By Drug Class

·        AChE Inhibitors

·        Combined Drug

·        Cholinergic

·        Immunoglobulins

·        Memantine

Market By Distribution Channel

·        Retail Pharmacy

·        Online Sales

·        Hospital Pharmacy

Alzheimer’s Disease Treatment Market Leading Companies

This section of the study honors the market's top vendors AB Science, AbbVie Inc., Allergan, AC Immune, AstraZeneca, Bayer AG, Biogen, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, H. Lundbeck A/S, Johnson & Johnson Services, Inc., Merz Pharma, Novartis AG, ONO PHARMACEUTICAL CO., LTD., Pfizer Inc., Takeda Pharmaceutical Company Limited., TauRx, Teva Pharmaceutical Industries Ltd., and VTV Therapeutics.

Alzheimer’s Disease Treatment Market Regions

North America

·         U.S.

·         Canada

Europe

·         U.K.

·         Germany

·         France

·         Spain

·         Rest of Europe

Latin America

·         Brazil

·         Mexico

·         Rest of Latin America

Asia-Pacific

·         China

·         Japan

·         India

·         Australia

·         South Korea

·         Rest of Asia-Pacific

Middle East & Africa

·         GCC

·         South Africa

·         Rest of Middle East & Africa